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During 2012, the Association for Professionals in Infection Control
and Epidemiology (APIC) and the Society for Healthcare Epidemi-
ology of America (SHEA) published a position paper highlighting
the critical importance of infection preventionists (IPs) and health
care epidemiologists (HEs) in effective antimicrobial stewardship
(AS) programs.1 AS refers to collaborative, coordinated programs and
interventions designed to improve antimicrobial prescribing (ie, right
drug, dose, duration, and route of administration when antibiotics
are needed) to optimize clinical outcomes while minimizing un-
intended consequences of antimicrobial agent use such as toxicity,
selection of pathogenic organisms, and emergence of resistance.2,3
In the intervening 5 years, much has happened to garner na-
tional and regulatory attention to the growing problem of
antimicrobial resistance (AMR) and the importance of AS and the
concomitant stewardship of diagnostic testing as strategies to slow
the emergence of resistant organismswhile limiting unintended con-
sequences such as selecting for resistant pathogens and the
development of Clostridium diﬃcile infection (CDI). This paper
updates and reaﬃrms the critical role of IPs and HEs in the pre-
vention and control of health care-associated infections (HAIs),
particularly those caused bymultidrug-resistant organisms (MDROs).
The key supporting role of infection prevention and control (IPC)
programs in advancing the synergistic strategy of AS alongside phy-
sician and pharmacist AS leaders is also highlighted.
Three watershed events occurred in recent years to increase AMR
and AS awareness among health care providers, policy makers, and
the public. First, the human and economic cost of AMR in the United
States was revealed in the Centers for Disease Control and Preven-
tion (CDC) report, Antibiotic Resistance Threats in the United States,
2013.4 Using conservative estimates, the CDC determined that
antibiotic-resistant organisms are responsible formore than 2million
infections and 23,000 deaths per year in the United States, at a direct
cost of $20 billion.4 This report provided the ﬁrst comprehensive
snapshot of dangers posed by antibiotic-resistant organisms in the
United States, categorizing these hazards as urgent, serious, or con-
cerning. A subsequent, and perhaps more sobering 2014 report
commissioned by the UK Prime Minister and the Wellcome Trust
suggested that without global action, 10 million deaths from AMR
infections will occur worldwide by 2050.5 Second, in response to
this escalating problem, in 2014 President Obama implemented the
National Strategy on Combating Antibiotic Resistant Bacteria through
Executive Order 13676, followed in March 2015 by release of the
National Action Plan for Combating Antibiotic-Resistant Bacteria,6 which
outlines speciﬁc actions to be taken to implement the strategy. The
action plan provides a 5-year roadmap outlining critical actions by
key federal departments and agencies, as well as goals, mile-
stones, and metrics for measuring progress. Of speciﬁc interest to
IPs and HEs are actions for major reductions in the incidence of
urgent and serious threats, including carbapenem-resistant Entero-
bacteriaceae, methicillin-resistant Staphylococcus aureus, and CDI;
improved AS across all health care settings; and enhanced capac-
ity to prevent the spread of resistant infections.6 Third, following
release of the action plan, the White House convened the ﬁrst-
ever Forum on Antibiotic Stewardship and established the
Presidential Advisory Council on Combating Antibiotic Resistant Bac-
teria. The Forum brought together 150 key human and animal health
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constituencies involved in AS, providing participants the opportu-
nity to exchange ideas on ways public and private sectors can work
together to improve responsible use of antibiotics, as well as commit
to action.7 The Advisory Council provides advice, information, and
recommendations to the Secretary of Health and Human Services
regarding programs and policies intended to support and evaluate
the implementation of federal activities related to combating
antibiotic-resistant bacteria.8 Of note, the 2015 APIC, SHEA, and
Society of Infectious Diseases Pharmacists (SIDP) presidents par-
ticipated in the Forum on Antibiotic Stewardship and the 2017 APIC
and SHEA presidents gave presentations during the Advisory Council
meeting for nonfederal stakeholders during January 2017.
These 3 events directly inﬂuenced the development of subse-
quent reports and recent regulatory mandates that highlight the key
supporting role of IPC programs in advancing successful AS inter-
ventions across the entire continuum of patient care, including:
• CDC Core Elements of Hospital Antibiotic Stewardship Programs,9
CDC Core Elements of Antibiotic Stewardship for Nursing
Homes,10 CDC Core Elements of Outpatient Antibiotic
Stewardship,11 and Implementation of Antibiotic Stewardship
Core Elements at Small and Critical Access Hospitals.12 Each doc-
ument identiﬁes key structural and functional aspects of effective
programs, and indicates that the work of physician and phar-
macist AS program leaders is greatly enhanced by the support
of other key groups, including IPC programs.
• National Quality Partners Playbook: Antibiotic Stewardship in
Acute Care.13 This comprehensive tool uses the CDC core ele-
ments as a framework and provides concrete strategies and
practical suggestions to guide hospitals in strengthening exist-
ing AS initiatives or creating successful AS programs from the
ground up.
• The Centers for Medicare and Medicaid Services new require-
ments for participation rule, effective in 2016, requires long-
term care (LTC) facilities to update their IPC program, including
requiring an IPC oﬃcer in 2019, and an AS program that in-
cludes antibiotic use protocols and a system tomonitor antibiotic
use to be implemented in 2017.14 The Centers for Medicare and
Medicaid Services proposed infection control conditions-of-
participation rule that requires AS programs in all acute care
and critical access hospitals is among the pending regulations
awaiting approval.
• The Joint Commission Antimicrobial Stewardship Standard
MM.09.01.01, effective January 1, 2017, requires hospitals, crit-
ical access hospitals, and nursing care centers have AS programs
based on current scientiﬁc publications, and to have an AS mul-
tidisciplinary team that includes IPs.15 The original standard
contained 8 elements of performance (EPs)15; however, effec-
tive October 1, EP 3 (The [critical access] hospital educates
patients, and their families as needed regarding the appropri-
ate use of antimicrobial medications, including antibiotics) was
deleted. This decision was based on feedback to The Joint Com-
mission that education for patients regarding speciﬁc
antimicrobial therapy they are receiving is already required under
other medication management standards and that the value of
general education on AS principles was unlikely to be re-
tained by hospitalized patients and families and would be more
appropriately delivered in outpatient settings.16
THE SYNERGY OF IPC AND AS PROGRAMS
IPC and AS are bound by a strong esprit de corps and shared
common goal—to keep patients safe and to improve patient out-
comes, regardless of where care is delivered. The increasing incidence
of MDRO infections has become a safety concern for patients across
the continuum of patient care. MRDO infections are more diﬃcult
to treat, incur greater treatment costs, and have greater morbidity
and mortality than infections caused by organisms susceptible to
antibiotics. Antibiotic misuse and overuse facilitates the develop-
ment of MDROs, as well as CDI infections – an antibiotic-associated
adverse drug event – making AS an important synergistic HAI pre-
vention and control strategy.17 In fact, a recent meta-analysis showed
AS programs reduced the incidence of infections and colonization
withmultidrug-resistant gram-negative bacteria, extended-spectrum
β-lactamase-producing gram-negative bacteria, and methicillin-
resistant S aureus, as well as the incidence of CDI infections.18
Furthermore, AS programs, when implemented alongside IPC mea-
sures, especially hand-hygiene interventions, were more effective
than implementation of AS alone—verifying that a well-functioning
IPC program is fundamental to a successful organizational AS
strategy.18 Similar data have also shown that the addition of AS in-
terventions can enhance results of robust IPC measures, particularly
when addressing an outbreak.19
AS programs have been shown to improve patient outcomes,
reduce antimicrobial agent-related adverse events, and decrease
AMR.18-21 To date, primary strategies include prescriber
preauthorization and prospective audit and feedback, with supple-
mental strategies such as guidelines and clinical pathway
development, intravenous-to-oral conversion protocols, limiting in-
appropriate culturing, and provider education.2,9-12 Changing practices
and prescribing patterns and learned behaviors of physicians, nurses,
pharmacists, and other health care providers will take time and in-
vestment, but is critical to affecting a long-term solution to the rise
of AMR and CDI infections. It is equally important that all clini-
cians depend on evidence-based IPC interventions to reduce demand
for antimicrobial agents by preventing infections from occurring in
the ﬁrst place, andmaking every effort to prevent transmissionwhen
they do. IP and HE leaders are credible IPC subject-matter experts
with additional social and behavioral skills to effectively engage the
different professional disciplines to promote, implement, support,
sustain, and evaluate IPC strategies across practice settings—many
of the same skills needed by those leading AS programs. IPC and
AS programs are intrinsically linked, making effective collabora-
tion essential to ensure patient safety.
The CDC identiﬁes core elements associated with successful AS
programs—7 elements for hospitals and LTC facilities9,10,12 and 4 el-
ements for outpatient facilities11—and provides a framework for
implementation. Tables 1 and 2 provide a description of each
element. APIC, SHEA, and SIDP support the CDC core elements as
an AS framework and believe the following related to the synergy
of IPC and AS:
1. Leadership commitment. Health care system leaders must pri-
oritize IPC and AS as part of wider patient safety strategies,
creating an infrastructure to promote, sustain, and dissemi-
nate best practices across the continuum of patient care. IPC and
AS program leaders must work together to align their pro-
grams, promoting communication and collaboration, and
reducing the likelihood of redundant initiatives. Given the
synergy between the programs, they should seize every oppor-
tunity to beneﬁt from each other’s expertise and organizational
inﬂuence and partnerwhenmaking the case for program support
and necessary resource allocation to clinical and administra-
tive leadership.
2. Accountability. AS programs are best led by infectious disease
(ID) physicians with clinical pharmacists with additional stew-
ardship training.2,3,9 Although this is the preferred approach,
assuming this additional responsibility may exceed the capac-
ity and/or capability of some ID physicians and/or clinical
pharmacists and be impractical for community and critical access
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hospitals, as well as nonacute settings such as ambulatory and
LTC facilities. As a result, in practice, AS programs are being led
by a variety of health care professionals, in a variety of
settings.22-25 Regardless of leadership model, it is imperative to
engage interested, local, and respected physician, pharmacist,
and nursing champions to help foster collaboration across spe-
cialty areas and to lend support for strong, empowered
leadership at the front line of patient care. Those engaged in
building, leading, and evaluating AS programs should seek to
acquire the core skills as outlined in the SHEAwhite paper, Guid-
ance for the Knowledge and Skills Required for Antimicrobial
Stewardship Leaders as listed in Table 3.22
3. Drug expertise. Most pharmacists are not formally trained in
ID, and the majority of health care facilities do not have access
to an ID pharmacist who is comfortable with AS.22,26 Health care
facilities should consider appointing general clinical pharma-
cists to ﬁll this role but should then require and fund additional
training in AS from entities such as the SIDP Making a Differ-
ence in Infectious Diseases program, or SHEA.27,28 Alternative
methods can also be used to gain access to ID physicians and
pharmacists, including pooling resources, employing external
stewardship consultants onsite or via telehealth, or seeking ad-
ditional expertise by joining multihospital improvement
collaboratives.12,29 When remote expertise is used, it is impor-
tant to have an AS program leader who is on staff at the
hospital.12
4. Action. Although IPs and HEs may not be involved in
preauthorization or prospective audit and feedback interven-
tions, they do engage a diverse range of clinical disciplines across
practice settings in HAI prevention. IPs have substantial contact
with bedside nurses, often together reviewing patients who
develop HAIs as part of routine daily activities. They can lever-
age these strong collegial relationships to inﬂuence and facilitate
nursing’s supporting role in initiating antibiotic timeouts, per-
forming antibiotic reconciliation during patient transitions of
care, and educating patients and families about safe and ap-
propriate antibiotic use.30-33 For example, a recent study found
that nurse prompting of antimicrobial review during daily rounds
can lead to signiﬁcant reduction in antimicrobial agent use, pro-
viding another mechanism of sustaining antimicrobial
awareness.34 Additionally, IPs and HEs often participate in unit-
based safety teams (eg, the Comprehensive Unit-Based Safety
Program) and can facilitate an interprofessional, unit-based dis-
cussion of AS needs by inviting relevant AS team members to
join the meetings. Furthermore, collaborative efforts to have the
stewardship team contact the IPC teamwhen they identify and/
or approve antibiotic therapy for patients with infections caused
by certain MDROs, and IP assistance in training bedside nurses
in appropriate culture techniques are examples of how IPs and
stewards can expand the capacity of both teams. Similar to IPC
interventions and actions, ﬂexibility and tailoring AS ap-
proaches to local needs is essential.
5. Tracking. Although not responsible for monitoring antibiotic pre-
scribing, IPC programs do perform surveillance for emerging
pathogens and resistance patterns, as well as rapid response to
every possible transmission. Use of the CDC National Health-
care Safety Network Antimicrobial Use and Resistance module
is highly effective because it provides a mechanism for facili-
ties to report and analyze antimicrobial agent use as part of AS
efforts at their facility.35 Standardized antimicrobial adminis-
tration ratio values can serve as a starting point for medication
use evaluations by AS programs. To successfully report to the
Antimicrobial Use and Resistance module, stewardship teams
will need to work closely with their IPC team to ensure that ap-
propriate data structures are developed and kept in alignment
for reporting. There are important implications for antimicro-
bial agent use based on how units are grouped, including
standardized antimicrobial administration ratio values only being
calculated for speciﬁc unit types. Therefore, to obtain the most
value from these data, the stewardship and IPC teams need to
be in constant contact regarding facility structure and other re-
porting considerations. These data will also beneﬁt the IPC team
because antibiotic use patterns are often a key element in out-
break investigations. Stewardship programs also have data
sources beyond the National Healthcare Safety Network and can
often provide electronic antibiotic use summaries on the patient
level, aiding the work of IPs and HEs.
6. Reporting. Although not responsible for reporting information
on antibiotic use, IPC programs are responsible for HAI surveil-
lance and providing feedback of infection rates (eg, MDRO and
CDI) and audit data (eg, hand hygiene adherence) to clinicians
and other stakeholders. CDI prevention is a high priority for IPC
and AS programs, so sharing and disseminating antibiotic use
and CDI infection rates is essential to prevention efforts.2 Pro-
viding feedback that is timely, frequent, individualized,
nonpunitive, and customized can be very inﬂuential in reduc-
ing HAIs and antimicrobial agent use.33,36-38 As more robust
antibiotic use benchmarking tools aremore fully developed, there
is a vital role of IPC programs to help educate and guide local
reporting patterns. Similar to HAI data, data on stewardship
efforts should be reported not just to providers, but also to ap-
propriate facility committees, such as the IPC, patient safety, and
medical executive committees, as well as the board of directors.
7. Education. Health care provider engagement is an essential com-
ponent for successful IPC and antibiotic resistance prevention
work. Creating educational strategies to address each disci-
pline’s clinical interests and make the case for why IPC and AS
is of value to them and their patients is essential.39 Education
should be team oriented and problem based, and are most ef-
fective when they include workshops, bedside teaching, and
simulation-based training.40 We encourage the participation of
IPs and HEs in designing and delivering AS-related education
to health care providers as well as to patients and their fami-
lies. This can often be done in collaboration with the AS team
to reach a broader andmore diverse audience with a single con-
sistent message of preventing infection and reducing MDROs.
A logical area for IPC education participation is to ensure that
front-line physicians and nurses are aware of the indications for
testing as well as the risks associated with inappropriate testing.
Some speciﬁc examples include indications for obtaining and
appropriate collection of urine cultures, indications for obtain-
ing culture from endotracheal tubes, and indications for testing
for CDI infections.
In addition to the CDC core elements, APIC, SHEA, and SIDP
further believe that microbiology laboratory staff members and clin-
ical microbiologists play an essential role in successful IPC and AS
programs, including:
• Diagnosis. The accurate and timely services provided by a mi-
crobiology laboratory supports the application of medical
knowledge and judgment to achieve the best outcomes for pa-
tients with an ID. The lab provides information to help determine
whether a patient is infected, what the pathogen is, and in most
cases the susceptibility of the organism. The laboratory pro-
vides interpretation and translation of the results into the day-
to-day infection management.41 Recent advances in molecular
diagnostic technologies have signiﬁcantly reduced the delay in
ID diagnosis, can identify and precisely characterize emerging
pathogens, and trace the source of outbreaks in a manner of
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days.42 It is essential for IPs, HEs, and the AS team to under-
stand the scope of these rapid diagnostic tests andwork together
to develop processes and interventions to assist clinicians in in-
terpreting and responding appropriately to results.2
• Guidance. To achieve the best results, microbiology cultures
should have an appropriate indication (right test at the right
time), be properly collected, and transported to a laboratory in
a timely manner before antibiotic agents are administered. The
inﬂuence of proper specimen collection is key in providing cli-
nicians accurate information to improve patient outcomes. A
clinician needs to have conﬁdence that the results are accu-
rate, clinically relevant, and signiﬁcant.43,44
• Advisement. To effectively use molecular diagnostic technolo-
gy for enhancement of IPC practices, it is important to
understand the scope of these rapid diagnostic tests and to ap-
preciate the need for judicious interpretation in collaboration
with a clinical microbiologist.42
SUMMARY
The issues surrounding the prevention and control of infec-
tions are intrinsically linked with the issues associated with the use
of antimicrobial agents and the proliferation and spread of MDROs.
The vital work of IPC and AS programs cannot be performed inde-
pendently and requires interdependent and coordinated action across
multiple and overlapping disciplines and clinical settings. Deliber-
ate strategic relationship-building actions will be required of IPC
and AS program leaders to bring groups together to achieve the larger
purpose of keeping patients safe from infection and ensuring that
effective antibiotic therapy is available for future generations.
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